$Barinthus Biotherapeutics (BRNS.US)$ NEWS Barinthus Bio Ann...
NEWS
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
Barinthus Bio announced positive topline data from the Phase 1b/2 APOLLO trial of VTP-200 in persistent high-risk human papillomavirus (HPV) infections. VTP-200 demonstrated positive trends in clearance rates for both high-risk HPV and cervical lesions in groups receiving the highest ChAdOx dose. However, there was no statistically significant improvement compared to the placebo group. The trial met its primary safety endpoint, showing VTP-200 was generally well-tolerated with no severe adverse events. Future development options are being evaluated with ongoing analyses.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1063Followers
65Following
7305Visitors
Follow